Key facts
- This page summarizes Thomas Englese's Form 4 filing for AZIYO BIOLOGICS, INC. (ELUT).
- 6 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 10 Mar 2022, 19:46.
Thomas Englese - 08 Mar 2022 Form 4 Insider Report for AZIYO BIOLOGICS, INC. (ELUT)
- Reporting relationship
- CHIEF COMMERCIAL OFFICER
- Issuer ticker
- ELUT
- Reported as of
- 08 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Mar 2022, 19:46:06 UTC
- Prior SEC filing
- 15 Dec 2021
- Next SEC filing
- 12 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Hamet, Attorney-in-Fact for Thomas Englese
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Thomas Englese filed Form 4 for AZIYO BIOLOGICS, INC. (ELUT) on 10 Mar 2022.
Change
- Previous filing in this sequence was filed on 15 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AZYO
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +938
- Change %
- +16%
- Price
- $0.000000
- Shares after
- 6,883
- Date
- 08 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F2
AZYO
transaction
Class A Common Stock
Sale
- Transaction value
- Shares
- -276
- Change %
- -4%
- Price
- Shares after
- 6,607
- Date
- 10 Mar 2022
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AZYO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +31,000
- Change %
- Price
- $0.000000
- Shares after
- 31,000
- Date
- 08 Mar 2022
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 31,000
- Exercise price
- $5.08
- Footnotes
- F4
AZYO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +8,700
- Change %
- Price
- $0.000000
- Shares after
- 8,700
- Date
- 08 Mar 2022
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 8,700
- Exercise price
- Footnotes
- F5, F6
AZYO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -938
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 2,812
- Date
- 08 Mar 2022
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 938
- Exercise price
- Footnotes
- F1, F7
AZYO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +15,390
- Change %
- Price
- $0.000000
- Shares after
- 15,390
- Date
- 08 Mar 2022
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 15,390
- Exercise price
- Footnotes
- F5, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.
Footnote F2
Includes 857 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.34. The Reporting Person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F4
The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.
Footnote F5
Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.
Footnote F6
The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.
Footnote F7
On March 8, 2021, the Reporting Person was granted 3,750 restricted stock units, vesting in four substantially equal annual installments beginning in March 8, 2022.
Footnote F8
The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.